Xprab Vaccine is a human rabies vaccine formulated with 150 IU of purified rabies antigen per dose, designed to provide active immunization against rabies virus infection. It is indicated for pre-exposure prophylaxis in individuals at high risk of rabies exposure, such as veterinarians, laboratory personnel, animal handlers, and travelers to endemic areas, as well as for post-exposure prophylaxis following potential rabies virus exposure through animal bites or scratches. The vaccine stimulates the immune system to produce virus-neutralizing antibodies, thereby preventing the onset of rabies, a fatal viral encephalitis. Xprab Vaccine is administered intramuscularly according to recommended immunization schedules, which typically include multiple doses to ensure adequate immunogenicity. It is important to initiate post-exposure prophylaxis as soon as possible after exposure, combining wound management, rabies immunoglobulin administration when indicated, and vaccination. The vaccine is contraindicated in individuals with known hypersensitivity to any component of the formulation. Common adverse reactions are generally mild and transient, including injection site pain, erythema, and low-grade fever. Xprab Vaccine should be stored and handled according to manufacturer guidelines to maintain potency and efficacy. Proper administration and adherence to vaccination schedules are essential to achieve optimal protection against rabies infection.